Margarida Maria Barroso

Ms. Margarida Maria Barroso

Universities of Giessen and Marburg Lung Center, Gießen, Hesse, Germany
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2022 in Cells
Verified
Journal Article
Open access
PDF file
AVAna Ivonne Vazquez-Armendariz
Ana Ivonne Vazquez-Armendariz
MBMargarida Maria Barroso
Margarida Maria Barroso
EAElie El Agha
Elie El Agha
SHSusanne Herold
Susanne Herold
Idiopathic pulmonary fibrosis (IPF) is a progressive and often lethal interstitial lung disease of unknown aetiology. IPF is characterised by myofibroblast activation, tissue stiffening, and alveolar epithelium injury. As current IPF treatments fail to halt disease progression or induce regeneration, there is a pressing need for the development of novel therapeutic targets. In this regard, tri-dimensional (3D) models have rapidly emerged as powerful platforms for disease modelling, drug screening and discovery. In this review, we will touch on how 3D in vitro models such as hydrogels, precision-cut lung slices, and, more recently, lung organoids and lung-on-chip devices have been generated and/or modified to reveal distinct cellular and molecular signalling pathways activated during fibrotic processes. Markedly, we will address how these platforms could provide a better understanding of fibrosis pathophysiology and uncover effective treatment strategies for IPF patients.

20 June 2022 in Cells
Verified
Journal Article
Open access
PDF file
VKVahid Kheirollahi
Vahid Kheirollahi
AKAli Khadim
Ali Khadim
GKGeorgios Kiliaris
Georgios Kiliaris
MKMartina Korfei
Martina Korfei
MBMargarida Maria Barroso
Margarida Maria Barroso
EAElie El Agha
Elie El Agha
Insulin-like growth factor (IGF) signaling controls the development and growth of many organs, including the lung. Loss of function of Igf1 or its receptor Igf1r impairs lung development and leads to neonatal respiratory distress in mice. Although many components of the IGF signaling pathway have shown to be dysregulated in idiopathic pulmonary fibrosis (IPF), the expression pattern of such components in different cellular compartments of the developing and/or fibrotic lung has been elusive. In this study, we provide a comprehensive transcriptional profile for such signaling components during embryonic lung development in mice, bleomycin-induced pulmonary fibrosis in mice and in human IPF lung explants. During late gestation, we found that Igf1 is upregulated in parallel to Igf1r downregulation in the lung mesenchyme. Lung tissues derived from bleomycin-treated mice and explanted IPF lungs revealed upregulation of IGF1 in parallel to downregulation of IGF1R, in addition to upregulation of several IGF binding proteins (IGFBPs) in lung fibrosis. Finally, treatment of IPF lung fibroblasts with recombinant IGF1 led to myogenic differentiation. Our data serve as a resource for the transcriptional profile of IGF signaling components and warrant further research on the involvement of this pathway in both lung development and pulmonary disease.

9 March 2023
Verified
Conference Paper
Closed access
MBMargarida Maria Barroso
Margarida Maria Barroso
AVA I Vázquez-Armendariz
A I Vázquez-Armendariz
LJL Jankauskaite
L Jankauskaite
IAI Alexopoulos
I Alexopoulos
SGS Günther
S Günther
SHS Herold
S Herold
Mesenchymal stem cells (MSC) show promising therapeutic potential, but it is unclear how they sense injury during viral lung infections. We aimed to understand how bone marrow derived-MSC (BM-MSC) can sense injury during influenza virus (IV) infection and how can they be primed to improve their protective effects. Using IV-infected alveolar epithelial cells (iAEC)/MSC co-culture systems together with our established bronchioalveolar lung organoid (BALO) model it was possible to compare the extent of epithelial cell proliferation and differentiation supported by either lung resident MSC (rMSC) or BM-MSC. Strikingly, pre-conditioning with soluble factors from iAEC or from bronchoalveolar lavage fluid significantly enhanced the capacity of BM-MSC to drive alveolarization in BALO. Although cell differentiation capacity of BALO using BM-MSC was lower than rMSC, both cell types, when in co-culture with iAEC, displayed similar protective effects. Intra-tracheal (IT) BM-MSC application in WT or IFNAR-/- mice lead to a reduction of viral load and AEC infection-associated apoptosis, while significantly improving mice survival. Bulk-RNA sequencing of flow sorted IT-delivered-BM-MSC revealed that interferon-related genes and IL-11 were upregulated in iAEC and BM-MSC. Notably, IL-11 release in BM-MSC proved to be dependent on BM-MSC activation by type I IFN signalling, with this communication significantly contributing to iAEC resilience. In summary, type I IFN/IL-11 signaling axis could represent a promising target for the development of human MSC therapies.